ES2784316T3 - 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo - Google Patents
1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo Download PDFInfo
- Publication number
- ES2784316T3 ES2784316T3 ES16723592T ES16723592T ES2784316T3 ES 2784316 T3 ES2784316 T3 ES 2784316T3 ES 16723592 T ES16723592 T ES 16723592T ES 16723592 T ES16723592 T ES 16723592T ES 2784316 T3 ES2784316 T3 ES 2784316T3
- Authority
- ES
- Spain
- Prior art keywords
- pyridin
- indoline
- carboxamide
- fluoro
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*(C)c1cncc(*)n1 Chemical compound C*(C)c1cncc(*)n1 0.000 description 8
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154523P | 2015-04-29 | 2015-04-29 | |
| PCT/US2016/030105 WO2016176571A1 (en) | 2015-04-29 | 2016-04-29 | 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2784316T3 true ES2784316T3 (es) | 2020-09-24 |
Family
ID=56015108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16723592T Active ES2784316T3 (es) | 2015-04-29 | 2016-04-29 | 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9676758B2 (https=) |
| EP (1) | EP3292114B1 (https=) |
| JP (1) | JP6673939B2 (https=) |
| KR (1) | KR20180004193A (https=) |
| CN (1) | CN108174603B (https=) |
| AU (1) | AU2016255510A1 (https=) |
| BR (1) | BR112017022987A2 (https=) |
| CA (1) | CA2984153A1 (https=) |
| CL (1) | CL2017002738A1 (https=) |
| EA (1) | EA034244B1 (https=) |
| ES (1) | ES2784316T3 (https=) |
| IL (1) | IL255185A0 (https=) |
| MX (1) | MX373876B (https=) |
| PH (1) | PH12017501961A1 (https=) |
| WO (1) | WO2016176571A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111792990A (zh) * | 2019-04-09 | 2020-10-20 | 中国科学院上海药物研究所 | 一种不饱和酮类化合物、其制备方法和用途 |
| CA3156474A1 (en) * | 2019-11-08 | 2021-05-14 | Heptares Therapeutics Limited | GPR52 MODULATING COMPOUNDS |
| GB202003668D0 (en) | 2020-03-13 | 2020-04-29 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| BR112022018996A2 (pt) * | 2020-03-30 | 2022-11-01 | Boehringer Ingelheim Int | 3-fenoxiazetidin-1-il-pirazinas substituídas apresentando atividade agonística do gpr52". |
| TW202206413A (zh) * | 2020-04-22 | 2022-02-16 | 美商紐羅克里生物科學有限公司 | Gpr52調節劑及其使用方法 |
| GB202013558D0 (en) | 2020-08-28 | 2020-10-14 | Heptares Therapeutics Ltd | GRP52 Modularor compounds |
| EP4330232A1 (en) | 2021-04-26 | 2024-03-06 | Neurocrine Biosciences, Inc. | Gpr52 modulators and methods of use |
| US12115157B2 (en) | 2021-09-14 | 2024-10-15 | Boehringer Ingelheim International Gmbh | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament |
| GB202113186D0 (en) | 2021-09-15 | 2021-10-27 | Heptares Therapeutics Ltd | GPR52 Modulator compounds |
| WO2024091541A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
| JP2026508053A (ja) * | 2022-10-26 | 2026-03-10 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｇｐｒ５２モジュレーターとしての化合物および組成物 |
| WO2024091542A1 (en) * | 2022-10-26 | 2024-05-02 | Neurocrine Biosciences, Inc. | Compounds and compositions as gpr52 modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2043744A2 (en) * | 2006-07-13 | 2009-04-08 | SmithKline Beecham Corporation | Chemical compounds |
| WO2009107391A1 (ja) * | 2008-02-27 | 2009-09-03 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| FR2928645A1 (fr) * | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| JPWO2009157196A1 (ja) * | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| US20100041891A1 (en) | 2008-08-12 | 2010-02-18 | Takeda Pharmaceutical Company Limited | Amide compound |
| AR077214A1 (es) * | 2009-06-24 | 2011-08-10 | Neurocrine Biosciences Inc | Heterociclos nitrogenados y composiciones farmaceuticas que los contienen |
| JP2012082175A (ja) * | 2010-10-14 | 2012-04-26 | Daiichi Sankyo Co Ltd | インドリン化合物を含有する医薬組成物 |
-
2016
- 2016-04-29 KR KR1020177034516A patent/KR20180004193A/ko not_active Withdrawn
- 2016-04-29 WO PCT/US2016/030105 patent/WO2016176571A1/en not_active Ceased
- 2016-04-29 EA EA201792375A patent/EA034244B1/ru not_active IP Right Cessation
- 2016-04-29 ES ES16723592T patent/ES2784316T3/es active Active
- 2016-04-29 BR BR112017022987A patent/BR112017022987A2/pt not_active Application Discontinuation
- 2016-04-29 CA CA2984153A patent/CA2984153A1/en not_active Abandoned
- 2016-04-29 AU AU2016255510A patent/AU2016255510A1/en not_active Abandoned
- 2016-04-29 US US15/143,026 patent/US9676758B2/en active Active
- 2016-04-29 EP EP16723592.8A patent/EP3292114B1/en active Active
- 2016-04-29 MX MX2017013853A patent/MX373876B/es active IP Right Grant
- 2016-04-29 CN CN201680038190.3A patent/CN108174603B/zh active Active
- 2016-04-29 JP JP2017556818A patent/JP6673939B2/ja active Active
-
2017
- 2017-10-22 IL IL255185A patent/IL255185A0/en unknown
- 2017-10-27 PH PH12017501961A patent/PH12017501961A1/en unknown
- 2017-10-30 CL CL2017002738A patent/CL2017002738A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9676758B2 (en) | 2017-06-13 |
| CN108174603B (zh) | 2021-07-02 |
| EA201792375A1 (ru) | 2018-05-31 |
| CN108174603A (zh) | 2018-06-15 |
| KR20180004193A (ko) | 2018-01-10 |
| EP3292114B1 (en) | 2020-03-11 |
| CL2017002738A1 (es) | 2018-06-01 |
| WO2016176571A1 (en) | 2016-11-03 |
| JP6673939B2 (ja) | 2020-04-01 |
| MX373876B (es) | 2020-03-26 |
| JP2018519253A (ja) | 2018-07-19 |
| CA2984153A1 (en) | 2016-11-03 |
| BR112017022987A2 (pt) | 2018-07-24 |
| IL255185A0 (en) | 2017-12-31 |
| MX2017013853A (es) | 2018-06-07 |
| EA034244B1 (ru) | 2020-01-21 |
| EP3292114A1 (en) | 2018-03-14 |
| US20160318911A1 (en) | 2016-11-03 |
| AU2016255510A1 (en) | 2017-11-23 |
| PH12017501961A1 (en) | 2018-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2784316T3 (es) | 1-Heteroaril-indolin-4-carboxamidas como moduladores de GPR52 útiles para el tratamiento o la prevención de trastornos relacionados con el mismo | |
| JP5406716B2 (ja) | インドール化合物 | |
| TWI415845B (zh) | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 | |
| ES2353247T3 (es) | Derivados de (1h-indol-7-il)-pirimidin-2-il-amino)metadona y compuestos emparentados como inhibidores del igf-ri, para el tratamiento de cancer. | |
| AU2012312305B2 (en) | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | |
| ES2381895T3 (es) | Inhibidores de PI 3-quinasa y métodos para su uso | |
| WO2021197464A1 (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| BR112021002327A2 (pt) | derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4,5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona e compostos relacionados como inibidores de ptpn11(shp2) para o tratamento do câncer | |
| TWI473803B (zh) | 作為阿伐７正向異位調節劑之嗎福啉基噻唑 | |
| CA3121236A1 (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors | |
| US8999974B2 (en) | Acyl piperazine derivatives as TTX-S blockers | |
| RU2683245C1 (ru) | 6-членные гетероциклические производные и содержащая их фармацевтическая композиция | |
| JP2013523766A (ja) | キナーゼ阻害剤としてのイミダゾリル‐イミダゾール | |
| JP2013523658A (ja) | キナーゼ阻害剤としてのピラゾリル‐ピリミジン | |
| JP2010524962A (ja) | オーロラキナーゼ阻害剤のための創薬法 | |
| BR112019011825A2 (pt) | composto, enantiômero isolado, composição farmacêutica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em uma amostra biológica, método para inibir a atividade do transportador de monocarboxilato mct4, ou um mutante do mesmo, em relação ao transportador de monocarboxilato mct1, ou um mutante do mesmo, em um paciente, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 em um sujeito que necessite do mesmo, uso de um composto e método para obter um efeito em um paciente | |
| CN105980379A (zh) | 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用 | |
| ES3009813T3 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
| TW201713629A (zh) | 新穎苯并咪唑化合物及其醫藥用途 | |
| BR112019011758A2 (pt) | derivado de azaciclobutil triazol de grupo de anel condensado, método de preparação do mesmo e uso do mesmo em medicina | |
| ES2379242B1 (es) | Derivados de cromeno. | |
| US20110150834A1 (en) | Crth2 modulators | |
| CA3102458A1 (en) | Oga inhibitor compounds | |
| EA021067B1 (ru) | Производные бензотиазолона | |
| TWI564300B (zh) | 經取代之［（５Ｈ－吡咯［２，１－ｃ］［１，４］苯二氮呯－１１－基）哌嗪－１－基］－２，２－二甲基丙酸化合物作為雙重活性Ｈ１反向促進劑／５－ＨＴ2Ａ拮抗劑 |